Versigent (NYSE:VGNT) Cut to Equal Weight at Fox Advisors

Versigent (NYSE:VGNTGet Free Report) was downgraded by equities research analysts at Fox Advisors from an “overweight” rating to an “equal weight” rating in a report issued on Wednesday, Marketbeat Ratings reports.

Other equities analysts have also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Versigent from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Tuesday, July 7th. Wall Street Zen raised Versigent to a “hold” rating in a research report on Saturday, April 18th. BNP Paribas Exane initiated coverage on Versigent in a report on Tuesday, April 28th. They set an “outperform” rating and a $41.00 price target on the stock. Royal Bank Of Canada raised Versigent from a “sector perform” rating to an “outperform” rating and set a $52.00 price target on the stock in a research report on Wednesday. Finally, Evercore reissued an “outperform” rating and set a $60.00 price target on shares of Versigent in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Versigent has a consensus rating of “Buy” and an average target price of $50.58.

Get Our Latest Analysis on Versigent

Versigent Stock Up 9.0%

Shares of VGNT opened at $45.81 on Wednesday. Versigent has a one year low of $26.34 and a one year high of $50.88. The stock has a 50-day moving average price of $43.38.

Versigent (NYSE:VGNTGet Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.34. The firm had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.29 billion.

Further Reading

Analyst Recommendations for Versigent (NYSE:VGNT)

Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.